An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...
Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of ...
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...
Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...
The drug, vepdegestrant, failed to meaningfully delay cancer progression for all patients enrolled in the study but met its ...
Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...
The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...
Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...
Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.
Pfizer (NYSE:PFE) announced positive outcomes from the Phase 3 VERITAC-2 clinical trial, showing vepdegestrant's promise in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback